Back to Journals » OncoTargets and Therapy » Volume 2

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma

Authors Schwandt A, Wood LS, Rini B, Dreicer R

Published 16 March 2009 Volume 2009:2 Pages 51—61

DOI https://doi.org/10.2147/OTT.S4052

Review by Single anonymous peer review

Peer reviewer comments 6



Anita Schwandt1, Laura S Wood1, Brian Rini1,2, Robert Dreicer1,2

1Department of Solid Tumor Oncology; 2Taussig Cancer Institute and the Glickman Urological and Kidney Institute; Cleveland Clinic, Cleveland OH, USA

Abstract: Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.

Keywords: sunitinib, renal cell carcinoma, side effects, tyrosine kinase inhibitor

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.